Ranking Invest

OPT - Opthea Limited

Segmento: HealthcareOpthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Análise Ranking Invest

Valuation estimado
-$ 1.06 Bi
Valor de Mercado
$ 4.20 Bi
Desconto (AV)-494.3%
MLL
-0.21A companhia gerou lucro líquido equivalente a -21% do seu valor de mercado nos últimos 4 trimestres.
Último Balanço Atualizado: 2T2024

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

-$ 168.71 Mi

Dívida Líquida

$ 90.84 Mi

L4T

-$ 561.66 Mi

MM4T

-258036.81%

Indicadores Básicos

ROE

332.92%

Índices de Previsibilidade

Faturamento

1.88

Lucro

0.63

Margem

0.77

Índices de Tendência

Faturamento

1.60

Lucro

-10.74

Margem

-10.55

Índices de Endividamento

DIV/PAT

-0.54

DIV/L4T

-0.16

Dívidas
Cotação
Gráfico Lucro/Faturamento X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.